A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation

A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation

Abstract Background Studies carried out in vitro and in a mouse model have shown that BRAF inhibitors enhance the effects of IFN-α on BRAFV600E melanoma cells through the inhibition of ERK. Therefore, the combination of vemurafenib and IFN-α in patients with BRAFV600E melanoma may provide therapeuti...

Full description

Bibliographic Details
Main Authors: Ester Simeone, Giosuè Scognamiglio, Mariaelena Capone, Diana Giannarelli, Antonio M. Grimaldi, Domenico Mallardo, Gabriele Madonna, Marcello Curvietto, Assunta Esposito, Fabio Sandomenico, Francesco Sabbatino, Nicholas L. Bayless, Sarah Warren, SuFey Ong, Gerardo Botti, Keith T. Flaherty, Soldano Ferrone, Paolo A. Ascierto
Format: Article
Language:English
Published: BMC 2021-01-01
Series:Journal of Translational Medicine
Subjects:
Malignant melanoma
BRAF inhibitor
MAP kinase
Interferon
Online Access:https://doi.org/10.1186/s12967-020-02680-7

Internet

https://doi.org/10.1186/s12967-020-02680-7

Similar Items